You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 9,956,186

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,956,186

Title:	Use of cannabinoids in the treatment of epilepsy
Abstract:	The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of "treatment-resistant epilepsy" (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Inventor(s):	Guy; Geoffrey (London, GB), Wright; Stephen (London, GB), Mead; Alice (Cambridge, GB), Devinsky; Orrin (New York, NY)
Assignee:	GW Pharma Limited (Cambridge, GB)
Application Number:	15/449,204
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,956,186
Patent Claims:	1. A method of reducing convulsive seizure frequency in a patient with a treatment-resistant epilepsy, which is Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) .DELTA.9-tetrahydrocannabinol (THC), wherein the dose of the CBD is at least 10 mg/kg/day. 2. The method of claim 1, wherein the CBD comprises .DELTA.9-tetrahydrocannabinol (THC). 3. The method of claim 1, wherein the dose of at least 10 mg/kg/day is reached by beginning at a dose of 5 mg/kg/day and increasing by 2 to 5 mg/kg increments to at least 10 mg/kg/day. 4. The method of claim 1, wherein the dose of the CBD is 10 mg/kg/day. 5. The method of claim 1, wherein the dose of the CBD is 12 mg/kg/day. 6. The method of claim 1, wherein the dose of the CBD is 14 mg/kg/day. 7. The method of claim 1, wherein the dose of the CBD is 15 mg/kg/day. 8. The method of claim 1, wherein the dose of the CBD is 16 mg/kg/day. 9. The method of claim 1, wherein the dose of the CBD is 18 mg/kg/day. 10. The method of claim 1, wherein the dose of the CBD is 20 mg/kg/day. 11. A method of treating convulsive seizures in a patient with a treatment-resistant epilepsy, which is Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) .DELTA.9-tetrahydrocannabinol (THC), wherein the dose of the CBD is at least 10 mg/kg/day.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.